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Abstract In a study of elderly AML patients treated with the
hypomethylating agent decitabine (DAC), we noted a surpris-
ingly favorable outcome in the (usually very unfavorable)
subgroup with two or more autosomal monosomies (MK2+)
within a complex karyotype (Lübbert et al., Haematologica
97:393-401, 2012). We now analyzed 206 myelodysplastic
syndrome (MDS) patients (88 % of 233 patients randomized
in the EORTC/GMDSSG phase III trial 06011, 61 of them
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with RAEBt, i.e. AML by WHO) with cytogenetics informa-
tive for MK status.. Endpoints are the following: complete/
partial (CR/PR) and overall response rate (ORR) and
progression-free (PFS) and overall survival (OS). Cytogenetic
subgroups are the following: 63 cytogenetically normal (CN)
patients, 143 with cytogenetic abnormalities, 73 of themMK-
negative (MK−), and 70 MK-positive (MK+). These MK+
patients could be divided into 17 with a single autosomal
monosomy (MK1) and 53 with at least two monosomies
(MK2+). ORR with DAC in CN patients: 36.1 %, in MK−
patients: 16.7 %, in MK+ patients: 43.6 % (MK1: 44.4 %,
MK2+ 43.3 %). PFS was prolonged by DAC compared to
best supportive care (BSC) in the CN (hazard ratio (HR)
0.55, 99 % confidence interval (CI), 0.26; 1.15, p=0.03) and
MK2+ (HR 0.50; 99% CI, 0.23; 1.06, p=0.016) but not in the
MK−, MK+, and MK1 subgroups. OS was not improved by
DAC in any subgroup. In conclusion, we demonstrate for the
first time in a randomized phase III trial that high-risk MDS
patients with complex karyotypes harboring two or more au-
tosomal monosomies attain encouraging responses and have
improved PFS with DAC treatment compared to BSC.
Keywords Monosomal karyotype . Adverse cytogenetics .
Hypomethylating agents . Azacytidine . Epigenetic therapy .
Elderly patients
Introduction
The treatment of elderly myelodysplastic syndrome
(MDS)/AML patients with a complex karyotype still poses
a highly unmet clinical need, given the low complete re-
sponse rate and high relapse rate even after standard
induction/consolidation chemotherapy or allogeneic trans-
plantation. Regarding non-curative AML treatment of
older patients in the randomized MRC trial AML14, com-
paring low-dose cytarabine to best supportive care (BSC),
patients with adverse cytogenetics (the majority with com-
plex karyotypes) had an equally dismal outcome in both
treatment arms, with a median survival of less than
2 months and a 1-year survival below 5 % [1]. Not surpris-
ingly, a complex karyotype thus scores in the very high-
risk cytogenetic groups of AML and MDS [2–5]. Notably,
it recently became apparent that clofarabine and the DNA
hypomethylating agents azacytidine and decitabine (DAC)
have marked activity in complex-karyotype AML [6–9]
and MDS [10–16]. However, it is unclear why these drugs
differ from cytarabine and other cytotoxic agents in that
regard. Equally notable was the recurrent observation of
activity of DAC [13, 15–18] and azacytidine [10, 19] in
MDS/AML patients with sole monosomy 7—also a robust
clinical result but as yet lacking a mechanistic explanation.
A monosomy might be only one of several abnormalities
and may not exhibit prognostic impact itself [20, 21].
We therefore recently hypothesized that AML patients
with complex karyotype (CK+) including one or more au-
tosomal monosomies (MK+, most frequently monosomy
7) might show a response to hypomethylating agent treat-
ment that is absent in complex-karyotype patients without
autosomal monosomies (MK−/CK+). Since the large phase
II DAC trial 00331 had recruited 54 CK+ patients, their
outcome was compared with regard to the presence (MK+/
CK+, n=37) or absence (MK−/CK+, n=17) of the
monosomal karyotype [8]. Intriguingly, the response rate
was superior in the MK+/CK+ AML patients compared to
MK−/CK+ patients (complete plus partial remissions 37
vs. 12 %). Seemingly paradoxical was the result in the
group of 22 patients with at least two monosomies
(MK2+): these patients showed a 45 % complete remission
(CR)/partial remission (PR) rate vs. 25 % in the 15 patients
with a single monosomy (MK1) [8].
To extend this observation (collected from a single
AML trial) also to higher-risk MDS, we now conducted
identical cytogenetic subgroup analyses on 206 higher-
risk MDS patients (FAB classification) with informative
cytogenetics included in the randomized phase III trial
06011 of the EORTC Leukemia Group and the German
MDS Study Group [11] (constituting, after the recent re-
port of a subgroup analysis of the RAEBt patients [22], the
second subgroup analysis from this study; for a listing of
the Study Consortium see Supplementary Information).
We also provide supportive evidence from 118 additional
higher-risk MDS patients from two phase II DAC trials
[13].
Key findings are a comparable rate of overall and objective
responses to DAC in the normal karyotype and MK+ patients,
and prolonged progression-free (though not overall) survival
in patients with complex karyotype and two or more autoso-
mal monosomies treated with DAC compared to best support-
ive care. The in vivo mechanism of action of DAC in these
patients may be distinct from standard chemotherapy such as
low-dose AraC.
Patients and methods
Patients were eligible for the EORTC Leukemia Cooperative
Group phase III trial 06011 [11] if aged ≥60 years and diag-
nosed with primary or treatment-related MDS or chronic
19 UPMC, UMRS 872 and Saint-Antoine Hospital, AP-HP,
Paris, France
20 Department of Hematology, Haga Hospital, The
Hague, The Netherlands
192 Ann Hematol (2016) 95:191–199
myelomonocytic leukemia (CMMoL) irrespective of white
blood counts; IPSS intermediate-1, IPSS intermediate-2, or
high; bone marrow blasts 11–30 %; or ≤10 % but with poor
cytogenetics (IPSS) and ECOG performance status 0–2. Se-
vere cardiovascular disease was an exclusion criterion, where-
as previous treatment of MDS was not (except aggressive
chemotherapy or treatment with a hypomethylating agent).
The study was performed in accordance with the Declaration
of Helsinki, all patients provided written informed consent,
and the study was approved by the local ethics committees
at all participating trial sites. The definition of monosomal
karyotype was as by Breems et al. [23], i.e., at least two auto-
somal monosomies or one single autosomal monosomy in
combination with at least one structural abnormality.
Statistical analysis
Responses were assessed according to the International Work-
ing Group criteria [24, 25], with sequential bone marrow stud-
ies planned after every other course of decitabine and at weeks
24 and 48 for patients on the BSC arm, earlier in both arms in
case of suspected progression. Before and during the study,
evaluations of bone marrow aspirates were performed locally
by the investigators.
Progression-free survival (PFS) was defined as time
from random assignment to progression, relapse after
attainment of complete remission (CR) or partial re-
sponse (PR), or death, whichever occurred first. Overall
survival (OS) was defined as time from randomization
until death (whatever the cause) or the last follow-up
(censored observation). The Kaplan-Meier method was
used to estimate PFS and OS. The two-sided, log-rank
test was used for comparisons of treatment outcome.
The Cox proportional hazards model was used to obtain
hazard ratio (HR) estimates and corresponding confi-
dence intervals (CIs). Subgroup analyses were per-
formed using forest plot techniques. For efficacy analy-
ses, the intent-to-treat principle was followed.
Results
EORTC/GMDSSG randomized phase III trial 06011:
frequent recruitment of MDS patients with monosomal
karyotype
Of 233 patients randomized to either DAC or BSC, 206
had cytogenetic analyses allowing evaluation for the ab-
sence or presence of a monosomal karyotype (MK;
CONSORT information: Table 1, clinical characteristics:
Table 2). For the remaining 27 patients, cytogenetic
scoring for MK status was not feasible. As shown in
Table 3, 63 of the 206 patients were cytogenetically
normal (CN), and 143 had cytogenetic abnormalities
(CA). These CA patients can be subdivided into those
without (MK−, n=73) and with MK (MK+, n=70). Of
the MK− patients, 54 had one or two cytogenetic ab-
normalities (i.e., “non-complex,” MK−/CK−), and 18
had a complex karyotype (MK−/CK+). Among the
MK+ patients, four scored as CK−, the remaining 66
patients as CK+. Overall, this patient cohort has a
strong representation of very high-risk cytogenetic
patients.
DAC induces objective responses in all cytogenetic
subgroups including complex karyotypes with multiple
monosomies
Among all 206 patients with cytogenetics informative for
MK, the overall response rate (ORR, complete and partial
remissions, hematological improvement) was 33.3 % in the
105 patients on the DAC arm vs. 2 % on the BSC arm (two
patients had hematological improvement), making compari-
sons between the two treatment arms not very meaningful
(Table 3). We therefore focused on the ORR in the different
cytogenetic subgroups of the DAC arm. The 36 CN patients
had a 36.1%ORR, and the 69CA patients had a 31.9%ORR.
When next looking to the CA patients without MK (MK−, n=
30), an ORR of 16.7 % was seen, in the CA patients with MK
(MK+, n=39) an ORR of 43.6 %. Notably, this response rate
was comparable between patients with one (MK1, n=9,
44.4 %) and two or more monosomies (MK2+, n=30,
43.3 %), the latter generally being considered the cytogenetic
subgroup with the most adverse prognosis.







n (%) n (%)
Reason off-protocol
Normal completion 18 (17.8) 26 (24.8)
PD 49 (48.5) 36 (34.3)
Toxicity 0 (0.0) 19 (18.1)
Hypoplasia 0 (0.0) 5 (4.8)
Death 15 (14.9) 10 (9.5)
Refusal 12 (11.9) 3 (2.9)
Protocol violation 4 (4.0) 3 (2.9)
Ineligibility 1 (1.0) 1 (1.0)
Other 2 (2.0) 2 (1.9)
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Considering that these results might be skewed by a
lower rate of objective responses (CR, PR) and a higher
rate of hematological improvement in the cytogenetical-
ly less favorable compared to the cytogenetically more
favorable subgroups, we next looked to the CR/PR rate.
Here in the CN group, three and four patients had a CR
or PR, respectively (19.4 %); there were four CRs in
the MK− group (13.3 %) and seven CRs and two PRs
in the MK+ group (23.0 %). When dividing the MK+
group into MK1 and MK2+, the respective CR/PR rates
were 44.4 and 16.7 %.
Further support for the ability of DAC to induce objective
responses also in MK+ patients is provided by a retrospective
cytogenetic analysis we now performed of two phase II trials
of DAC in MDS [13]. One hundred eighteen of the 143 pa-
tients were informative for MK status (Supplementary
Table 1A). Here, the ORR was 48.3 % in the entire cohort,
46.7 % in the CN group, 46.6 % in the MK− group, and
60.0 % in the MK+ group (MK1, 66.7 %; MK2+, 58.3 %,
see Supplementary Table 1B).
Outcome with DAC vs. best supportive care in MDS
patients in different cytogenetic subgroups
To next address possible interactions between treatment and
cytogenetic subgroups, we looked to PFS and OS. For the
entire study cohort of the trial (233 patients) [11], for the
206 patients informative for MK status (Table 3), and for the
27 patients with unknown MK status (Supplementary
Figure 1), PFS but not overall survival (OS) was sensitive
enough to detect a significant effect of DAC treatment com-
pared to BSC.
When looking to the different cytogenetic groups, the CN
patients treated with DAC had a prolonged PFS (HR 0.55
[0.26; 1.15], p=0.03) but not OS compared to patients receiv-
ing sole BSC (Table 3, Figs. 1 and 2a, b). Among the 143
patients with any cytogenetic abnormalities, this difference in
PFS was not so impressive and did not reach statistical signif-
icance (HR 0.76 [0.49; 1.18], p=0.11). There was no differ-
ence in OS.
When dividing this group into MK− (n=73) and MK+ (n=
70), we first looked to the MK− patients: their median PFS
was 0.36 years with DAC treatment vs. 0.26 years with BSC
(HR 0.81 [0.43; 1.55], p=0.41). Median OS was 0.63 years in
MK− patients receiving DAC vs. 0.68 years in those receiving
BSC (HR 0.98 [0.49; 1.97], p=0.93), as shown in Table 3 and
Fig. 1b.
When dividing this MK− group into patients without or
with complex karyotype (CK), in the 54 MK−/CK− patients,
there seemed to be a trend towards longer PFS with DAC
treatment compared to BSC (HR 0.70 [0.33; 1.48], p=0.22)
that was not apparent in the 18 MK−/CK+ patients (HR 0.95
[0.26; 3.49], p=0.92). However, it should be stressed that such
trendmay also be due to the increasingly smaller patient group
sizes when conducting such comparisons. In both subgroups,
OS was similar between treatment arms (Table 3).
Among the 70 MK+ patients, by trend, DAC also seemed
to have a positive effect on PFS (median 0.47 years) when
compared to BSC (median 0.21 years; HR 0.73 [0.38; 1.38],
p=0.20). Here also, the OS was similar between the two treat-
ment modalities (HR 0.93 [0.49; 1.75], p=0.76).
Table 2 Patient baseline
characteristics (all patients, n=
233; patients informative for
monosomal karyotype, n=206)
Baseline characteristics Patients total (n=233) Patients informative for monosomal karyotype
(n=206)
DAC n=119 BSC n=114 DAC n=105 BSC n=101
Age, median (range) 69 (60; 90) 70 (60; 86) 69 (60; 90) 70 (60; 86)
>=75 years, n (%) 33 (27.7) 34 (29.8) 28 (26.7) 31 (30.7)
Sex, n (%)
Male 76 (63.9) 73 (64) 65 (61.9) 62 (61.4)
FAB, n (%)
RA/RARS 8 (6.7) 10 (8.8) 9 (8.5) 10 (9.9)
RAEB 61 (51.3) 64 (56.1) 52 (49.5) 59 (58.4)
RAEBt 40 (33.6) 35 (30.7) 34 (32.4) 27 (26.7)
AML 1 (0.8) 1 (0.9) 1 (1.0) 1 (1.0)
CMMoL 10 (8.4) 4 (3.5) 9 (8.6) 4 (4.0)
IPSS, n (%)
Low – – – –
Int 1 8 (6.7) 8 (7.0) 5 (4.8) 8 (7.9)
Int 2 64 (53.8) 63 (55.3) 55 (52.4) 52 (51.5)
High 46 (38.7) 42 (36.8) 45 (42.9) 41 (40.6)
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MDS patients with a complex karyotype harboring two
or more autosomal monosomies have longer
progression-free but not overall survival with DAC
compared to best supportive care
It is generally accepted that patients with AML/MDS and
more than a single autosomal monosomy have an inferior
outcome than those with MK1 when treated with standard
chemotherapy. We first subdivided the 70 MK+ into those
with one and two more monosomies, i.e., MK1 (n=17) and
MK2+ (n=53), respectively. As shown in Table 3, PFS in the
MK1 subgroup (n=17, four of them not fulfilling CK criteria)
was similar in both treatment arms (HR 0.88 [0.24; 3.24], p=
0.81), as was overall survival. Interestingly, median PFS of the
30 MK2+ patients treated with DAC was 0.45 years; com-
pared to 0.18 years in the 23 MK2+ patients treated with
BSC (Table 3, Fig. 2c), the resultant HR was 0.50 (0.23;
1.05], p=0.016). OS was not different between the two treat-
ment groups (Fig. 2d; HR 0.99 [0.47; 2.92], p=0.98, Table 3;
see also Fig. 2d).
Discussion
Already in 1997, Wijermans et al. [26] noted the ability of
DAC to induce remissions in MDS patients with complex
karyotype and other adverse cytogenetics. This—at first coun-
terintuitive—clinical finding was confirmed in MDS [27, 28]
and AML [7, 8]. While these trials were ongoing, Breems
et al. [23] first described the novel cytogenetic poor-risk cat-
egory of MK in AML. This genotype is clinically distinct: the
presence of one or more autosomal monosomies imbedded in
a complex karyotype was associated with a worse prognosis
than a complex karyotype without a monosomy. The presence
of two or more autosomal monosomies increases the negative
prognostic compared to a single monosomy impact, as shown
in several large AML and MDS patient series (standard che-
motherapy, allografting).
In order to confirm the intriguing response rates and overall
survival of MK AML patients observed in the 00331 trial, we
now analyzed MDS patients of the 06011 EORTC trial. Ask-
ing whether overall (ORR: CR/PR/HI) and objective response
rates (CR/PR) differed between these groups, we found that
for both, the MK+ patients had response rates comparable to
the CN group (cytogenetically low risk by IPSS). This encour-
aging finding is supported by a retrospective analysis of 118
higher-risk MDS patients for response by MK status treated
on two previous phase II DAC trials. We also had the chance
to cytogenetically analyze a large cohort of MDS patients
(mostly IPSS int-2/high) treated within a Dutch named-
patient azacytidine program (for patient characteristics see
Supplementary Table 2A). While it is difficult to compare
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program, when looking to ORR and CR/PR, some of the 26
MK+ patients treated with azacytidine also responded to this
hypomethylating agent, even in the MK2+ subgroup (n=17,
29.4 % ORR, 17.6 % CR/PR, Supplementary Table 2B). A
summarical tabulation of the outcome of all 319 DAC-treated
patients from the three data sets analyzed is provided in Sup-
plementary Table 3.
When analyzing the 06011 cohort for progression-free and
overall survival in the different cytogenetic subgroups
according to treatment arm, only the CN patients and those
with MK2+ (the two “extremes” within the prognostic
spectrum) treated with DAC had prolonged PFS compared
to those on the BSC arm; for the other cytogenetic sub-
groups, median PFS appeared similar. Overall survival was
not prolonged by DAC treatment, and possible reasons
have been discussed [11]. Briefly, four major factors could
be identified: (i) suboptimal DAC dose and schedule (3-
day dosing repeated every 6 weeks); (ii) DAC treatment
Fig. 1 Forest plots depicting a progression-free and b overall survival of
the different cytogenetic subgroups in the 06011 phase III trial by random
assignment. Patients with informative karyotype with normal
cytogenetics (CN) and abnormal cytogenetics without monosomal
karyotype (MK−) and with one (MK1) or two or more (MK2+)
monosomies were analyzed. DAC decitabine, BSC best supportive care,
O observed, E expected, Var variance, CI confidence interval, HR hazard
ratio 99 % CIs. Parentheses with asterisk indicate 95 % CIs for totals and
subtotals
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duration limited to 8 cycles (10 in CR patients); (iii) pa-
tient disposition, with a median duration from MDS diag-
nosis to randomization of only 3 months; and (iv) post-
progression treatment as a confounder. It would be of
interest to apply the specific scoring system recently de-
scribed by Oosterveld et al. for AML/MDS patients treat-
ed with standard chemotherapy, in which poor cytogenet-
ics predicted inferior survival [29].
Thus far, only very few studies have specifically ad-
dressed the role of MK in hypomethylating agent (HMA)
treatment. The largest azacytidine studies describe either a
similar overall survival of MDS patients with CK+/MK+ or
CK+/MK− [30] or a worse outcome of AML patients with
CK+/MK+ compared to CK+/MK− [31], albeit with limited
patient numbers. Our post hoc analysis constitutes the first
analysis of a phase III randomized HMA trial in MDS/
AML, but it has similar limitations: when comparing
cytogenetic subgroups of DAC-treated patients, the numbers
(particularly in the CK+/MK− group, n=9) became too
small to allow meaningful comparisons of outcomes. In that
regard, the test for interaction indicated in Fig. 1a was not
significant. However, the power of such a test is very low
given the limited number of patients (and events) analyzed.
Therefore, even if an interaction between MK status and the
treatment difference is observed, it cannot reach statistical
significance. If, however, several studies report the same
trend, it will become significant in a meta-analysis.
Collectively, our results provide further evidence that DAC
has encouraging activity in MDS/AML patients with a com-
plex karyotype including multiple monosomies. It is tempting
to speculate that this is mechanistically linked to the DNA
hypomethylating and gene-derepressive activity of this agent.
In future MDS/AML trials with HMAs, outcome by MK sta-
tus should be prospectively captured.
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Fig. 2 Progression-free (a, c) and overall survival (b, d) of patients of the
06011 phase III trial with normal karyotype (a, b) and MK2+ karyotype
(c, d) depicted by Kaplan-Meier plot according to treatment arm. Note
that two MK2+ patients receiving sole best supportive care (c) also lived
without progression of their MDS beyond 18 months.O observed events,
N patients, BSC treatment arm best supportive care, DAC treatment arm
DAC. a Progression-free survival in cytogenetically normal patients. b
Overall survival in cytogenetically normal patients. c Progression-free
survival in MK2+ patients. d Overall survival in MK2+ patients
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